Lupin obtains FDA OK for generic Travatan Z
Travoprost Ophthalmic Solution, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Lupin has received approval from the Food and Drug Administration for Travoprost Ophthalmic Solution, 0.004% (Ionic Buffered Solution), which is a generic of Sandoz’ s Travatan Z.
Travoprost Ophthalmic Solution, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The product will be manufactured at Lupin’s Pithampur facility in India.
[Read more: Lupin receives FDA nod for 3 generics]
Travoprost Ophthalmic Solution 0.004% had a market value of $77 million, per March 2024 IQVIA data.
[Read more: Lupin receives FDA OK for generic Banzel]